

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

SCYNEXIS is initiating a recall for BREXAFEMME due to potential cross-contamination of ibrexafungerp citrate drug substance with a non-antibacterial beta lactam drug substance being manufactured using equipment common to the manufacture of ibrexafungerp. The potential cross contamination with a nonantibacterial beta-lactam drug substance could lead to hypersensitivity reactions such as swelling, rash, urticaria and anaphylaxis, a potentially life-threatening adverse reaction.

Product: BREXAFEMME® (ibrexafungerp tablet) 150 mg cartons containing 4 tablets each

NDC: 75788-115-04

Lot Numbers: LF21000008, LF22000051